Did Eli Lilly Just Get a Leg Up on Novo Nordisk?

05:30am, Saturday, 13'th Jul 2024
Eli Lilly and Novo Nordisk compete in the diabetes and obesity care markets. Outside of weight loss, Lilly also has a strong portfolio of medicines used in cancer, plaque psoriasis, and more.
In the aftermath of Nvidia's (NASDAQ: NVDA ) historic trillion-dollar run, investors are scrambling to find the next potential trillion-dollar stocks to join the club. Quite a few contenders are neari
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Eli Lilly has earned approval for an Alzheimer's disease therapy. It's yet another blockbuster drug for its lineup.
Eli Lilly (NYSE: LLY) stock has been a winner for investors of late, owing largely to strong consumer demand for obesity drugs.
Even in the future, blue-chip stocks will be among the most reliable of all the available stocks. That's because they belong to businesses and companies with solid financials and growth potential.
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
We believe that Eli Lilly stock (NYSE: LLY) is currently a better pick than its industry peer – Pfizer stock , given its better prospects. PFE stock trades at a much lower multiple of 2.8x revenues,
Growth stocks have been in the spotlight since 1995. This year, Eli Lilly and the Vanguard Growth Index Fund ETF Shares have been top performers in the category.
'Mad Money' host Jim Cramer looks at what companies are in the running to join the elite $1 trillion club.
CNCB's Jim Cramer on Wednesday reviewed eight stocks that could join the coveted "trillion-dollar stock club," pinpointing Eli Lilly and Tesla as top contenders. Also on the list are Berkshire Hathawa
Pharmaceutical stocks have not set the world on fire, with a few exceptions. Since the pandemic ended, pharma stocks have largely fallen out of favor with investors amid declining sales and mixed fina
Affordability and supply are key challenges for GLP-1 weight loss drugs but these issues are actively being addressed, notes Maurits Pot. He and Rahul Jasuja assess the market opportunity of this part
In the most recent trading session, Eli Lilly (LLY) closed at $932.50, indicating a +1.58% shift from the previous trading day.
Shares in Novo Nordisk, maker of the wildly popular obesity drug Wegovy, were down 1.1% on Tuesday after the publication of a data analysis showing rival Eli Lilly's own treatment Mounjaro leads to fa
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE